About Rho GTPase-activating protein 19
Rho GTPase-activating protein 19 (ARHGAP19) is a protein
from Homo sapiens identified by UniProt accession
Q14CB8, 494 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | Rho GTPase-activating protein 19 |
| UniProt accession | Q14CB8 |
| Gene | ARHGAP19 |
| Organism | Homo sapiens |
| Length | 494 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (48)
Diseases linked to this target (Open Targets).
- body mass index · score 0.32
- monocyte count · score 0.32
- neutrophil count · score 0.30
- leukocyte count · score 0.27
- eosinophil count · score 0.25
- neutrophil-to-lymphocyte ratio · score 0.21
- type 2 diabetes mellitus · score 0.20
- electrocardiography · score 0.18
- grip strength measurement · score 0.18
- lymphocyte percentage of leukocytes · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14CB8-F1 | alphafold | PREDICTED | 69.65 | — |
Amino-acid sequence (494 residues)
MATEAQSEGE VPARESGRSD AICSFVICND SSLRGQPIIF NPDFFVEKLR HEKPEIFTEL VVSNITRLID LPGTELAQLM GEVDLKLPGG AGPASGFFRS LMSLKRKEKG VIFGSPLTEE GIAQIYQLIE YLHKNLRVEG LFRVPGNSVR QQILRDALNN GTDIDLESGE FHSNDVATLL KMFLGELPEP LLTHKHFNAH LKIADLMQFD DKGNKTNIPD KDRQIEALQL LFLILPPPNR NLLKLLLDLL YQTAKKQDKN KMSAYNLALM FAPHVLWPKN VTANDLQENI TKLNSGMAFM IKHSQKLFKA PAYIRECARL HYLGSRTQAS KDDLDLIASC HTKSFQLAKS QKRNRVDSCP HQEETQHHTE EALRELFQHV HDMPESAKKK QLIRQFNKQS LTQTPGREPS TSQVQKRARS RSFSGLIKRK VLGNQMMSEK KKKNPTPESV AIGELKGTSK ENRNLLFSGS PAVTMTPTRL KWSEGKKEGK KGFL
Explore Rho GTPase-activating protein 19 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets